GSK takes option to license hepatitis B RNA drugs from Ionis

Richard Staines | August 28, 2019

GSK takes option to license hepatitis B RNA drugs from Ionis
GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results. Ionis could receive up to $262 million, including a $25 million up front license fee, and tiered royalties in the low double digits on net sales. The two drugs, IONIS-HBVRX and IONIS-HBV-LRX, are part of a large portfolio of RNA-targeting drugs that Ionis is developing for big pharma clients. Other partnerships include Roche, Biogen, Bayer, and AstraZeneca, who like GSK are looking for pipeline drugs that have a good chance of making it through development and have significant sales potential if approved. GSK is not responsible for all development, regulatory and marketing activities and costs, assuming the deal is not challenged by US competition regulators. Under research chief Hal Barron, GSK is attempting to spice up its pipeline and is on the hunt for drugs with blockbuster-level potential. Barron is prepared to take some risks to achieve this goal after saying that the “play it safe” R&D culture that took hold at GSK under the previous management had failed to produce results. GSK’s revenues are still being propped up by its ageing respiratory blockbuster Advair, which finally faces generic competition in the US after potential challengers struggled to get approved by the FDA. CHB is a chronic viral infection of the liver that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Current treatments for patients with CHB provide low levels of hepatitis B virus S antigen seroclearance, leaving many patients without a treatment to achieve sustained disease remission. There are more than 200 million patients worldwide living with CHB.

Spotlight

Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. ... The most common forms are osteoarthritis (degenerative joint disease) and rheumatoid arthritis. Osteoarthritis usually occurs with age and affects the fingers, knees, and


Other News

Intent Data in the Age of Data Regulation

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while remaining compliant. In an article by John Snyder, CEO at Grapeshot, for Adexchanger, he says that the GDPR will remove 75% of third-party data and what’s left will be more expensive. This has caus...

Read More

TScan and Novartis partner to develop cancer therapies

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis will have rights of first negotiation for more targets and TCRs resulting from the alliance. TScan may develop TCRs that act on targets not licensed by Novartis. TScan Therapeutics president and CEO Davi...

Read More

BeiGene reports positive Phase III interim analysis for lung cancer drug

MedCity News | April 14, 2020

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with platinum chemotherapy and pemetrexed, compared with those receiving chemotherapy and pemetrexed alone. However, it did not disclose the data. The company said it plans to file for approval of the drug...

Read More

Would-be coronavirus drugs are cheap to make

Science | April 10, 2020

With a vaccine for the novel coronavirus still likely a year or more away, the first weapon against the virus could be one of the drugs now in clinical trials with COVID-19 patients. A new analysis out today shows that many of these drugs, which are currently manufactured or in development to treat other diseases, can be made for $1 a day per patient, or less. If any prove effective against the novel coronavirus, a coordinated international effort will be needed to ensure they are made affordable for people worldwide, the researchers argue. Scientists worldwide are conducting clinical trials on at least a dozen potential treatments for COVID-19. Some compounds have been on the market for dec...

Read More

Spotlight

Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. ... The most common forms are osteoarthritis (degenerative joint disease) and rheumatoid arthritis. Osteoarthritis usually occurs with age and affects the fingers, knees, and

Resources

Events